# InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. Developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—Sapu003 is a novel IV formulation of everolimus designed to overcome the limitations of oral mTOR inhibitors such as Afinitor (R), including poor bioavailability and restricted tumor penetration. The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer.

 To view the full press release, visit https://ibn.fm/Ut6V8

 About Oncotelic Therapeutics Inc.

 Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

 NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-oncotelic-therapeutics-inc-otcqb-otlc-announces-three-accepted-abstracts-on-deciparticle-tm-everolimus-sapu003-at-2025-san-antonio-breast-cancer-symposium/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/oncotelic-s-breast-cancer-therapy-to-debut-at-2025-san-antonio-symposium/c600fa6f0a6e98f644340ed188297d84) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202510/262346-oncotelic-therapeutics-announces-three-abstracts-on-deciparticle-everolimus-accepted-for-2025-san-antonio-breast-cancer-symposium)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202510/262349-oncotelic-therapeutics-presentara-tres-estudios-sobre-deciparticle-everolimus-en-simposio-de-cancer-de-mama-2025)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202510/262389-oncotelic-therapeutics-prasentiert-drei-abstracts-zu-neuartigem-brustkrebstherapeutikum-auf-san-antonio-symposium-2025)

Pickup - [https://actueclair.com](https://actueclair.com/202510/262380-oncotelic-therapeutics-presente-trois-etudes-sur-son-traitement-innovant-du-cancer-du-sein-au-symposium-de-san-antonio)

Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202510/262411-faq-oncotelic-therapeutics-deciparticletm-everolimus-presentations-at-2025-san-antonio-breast-cancer-symposium)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202510/262417-faq-oncotelic-therapeutics-deciparticletm-everolimus-presentations-at-2025-san-antonio-breast-cancer-symposium)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/23/mendontv.webp)